Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (NSCLC)
TW202629206APending Publication Date: 2026-07-16JANSSEN BIOTECH INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- TW114131635
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-03-12
- Filing Date
- 2025-08-19
- Publication Date
- 2026-07-16
Abstract
The present disclosure provides methods of using amivantamab in combination with lazertinib to treat non-small cell lung cancer (NSCLC).
Need to check novelty before this filing date? Find Prior Art